News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
712,219 Results
Type
Article (42184)
Company Profile (436)
Press Release (669599)
Section
Business (208683)
Career Advice (2021)
Deals (36001)
Drug Delivery (103)
Drug Development (83546)
Employer Resources (173)
FDA (16406)
Job Trends (15085)
News (352671)
Policy (33048)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (6)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (2636)
Accelerated approval (5)
Adcomms (24)
Allergies (82)
Alliances (50902)
ALS (88)
Alzheimer's disease (1409)
Antibody-drug conjugate (ADC) (124)
Approvals (16396)
Artificial intelligence (249)
Autoimmune disease (19)
Automation (14)
Bankruptcy (371)
Best Places to Work (11841)
BIOSECURE Act (18)
Biosimilars (102)
Biotechnology (330)
Bladder cancer (63)
Brain cancer (25)
Breast cancer (260)
Cancer (2074)
Cardiovascular disease (173)
Career advice (1686)
Career pathing (29)
CAR-T (147)
Cell therapy (420)
Cervical cancer (19)
Clinical research (67536)
Collaboration (812)
Compensation (473)
Complete response letters (24)
COVID-19 (2641)
CRISPR (40)
C-suite (223)
Cystic fibrosis (103)
Data (2017)
Decentralized trials (2)
Denatured (26)
Depression (46)
Diabetes (254)
Diagnostics (6397)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (119)
Drug pricing (104)
Drug shortages (26)
Duchenne muscular dystrophy (92)
Earnings (87462)
Editorial (35)
Employer branding (21)
Employer resources (147)
Events (115259)
Executive appointments (666)
FDA (17550)
Featured Employer (54)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (726)
Gene editing (105)
Generative AI (19)
Gene therapy (304)
GLP-1 (724)
Government (4469)
Grass and pollen (4)
Guidances (49)
Healthcare (19140)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (114)
Indications (27)
Infectious disease (2776)
Inflammatory bowel disease (139)
Inflation Reduction Act (11)
Influenza (49)
Intellectual property (88)
Interviews (311)
IPO (16768)
IRA (43)
Job creations (3700)
Job search strategy (1434)
Kidney cancer (9)
Labor market (34)
Layoffs (483)
Leadership (16)
Legal (7978)
Liver cancer (71)
Lung cancer (300)
Lymphoma (136)
Machine learning (4)
Management (58)
Manufacturing (277)
MASH (64)
Medical device (13477)
Medtech (13482)
Mergers & acquisitions (19709)
Metabolic disorders (667)
Multiple sclerosis (74)
NASH (19)
Neurodegenerative disease (93)
Neuropsychiatric disorders (30)
Neuroscience (1929)
NextGen: Class of 2025 (6755)
Non-profit (4546)
Northern California (2486)
Now hiring (37)
Obesity (362)
Opinion (220)
Ovarian cancer (74)
Pain (82)
Pancreatic cancer (77)
Parkinson's disease (144)
Partnered (20)
Patents (207)
Patient recruitment (98)
Peanut (47)
People (58486)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21215)
Phase II (29800)
Phase III (22044)
Pipeline (1082)
Podcasts (74)
Policy (121)
Postmarket research (2601)
Preclinical (9052)
Press Release (67)
Prostate cancer (97)
Psychedelics (37)
Radiopharmaceuticals (261)
Rare diseases (383)
Real estate (6009)
Recruiting (66)
Regulatory (22619)
Reports (46)
Research institute (2414)
Resumes & cover letters (351)
Rett syndrome (4)
RNA editing (4)
RSV (39)
Schizophrenia (72)
Series A (130)
Series B (84)
Service/supplier (11)
Sickle cell disease (56)
Southern California (2156)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (29)
Startups (3757)
State (2)
Stomach cancer (14)
Supply chain (61)
Tariffs (11)
The Weekly (46)
United States (21902)
Vaccines (676)
Venture capitalists (38)
Webinars (13)
Weight loss (244)
Women's health (35)
Worklife (16)
Date
Today (103)
Last 7 days (682)
Last 30 days (2715)
Last 365 days (34545)
2025 (8501)
2024 (36301)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27110)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (736)
Alabama (54)
Alaska (7)
Arizona (232)
Arkansas (14)
Asia (39125)
Australia (6515)
California (5713)
Canada (1891)
China (487)
Colorado (254)
Connecticut (268)
Delaware (131)
Europe (85431)
Florida (832)
Georgia (196)
Idaho (57)
Illinois (518)
India (24)
Indiana (296)
Iowa (10)
Japan (145)
Kansas (104)
Kentucky (24)
Louisiana (9)
Maine (61)
Maryland (854)
Massachusetts (4372)
Michigan (211)
Minnesota (377)
Mississippi (2)
Missouri (78)
Montana (29)
Nebraska (25)
Nevada (56)
New Hampshire (66)
New Jersey (1625)
New Mexico (30)
New York (1625)
North Carolina (989)
North Dakota (7)
Northern California (2486)
Ohio (195)
Oklahoma (14)
Oregon (37)
Pennsylvania (1276)
Puerto Rico (9)
Rhode Island (28)
South America (1108)
South Carolina (18)
South Dakota (1)
Southern California (2156)
Tennessee (95)
Texas (852)
Utah (167)
Virginia (134)
Washington D.C. (59)
Washington State (535)
West Virginia (3)
Wisconsin (50)
712,219 Results for "phanes therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Phanes Therapeutics Announces First Patient Dosed in Clinical Study of Peluntamig (PT217) in Combination with Chemotherapy
February 19, 2025
·
2 min read
Biotech Beach
Phanes Therapeutics, Inc. Announces Clinical Supply Agreement with Roche to Evaluate PT217 in Combination with an anti-PD-L1 Therapy
Phanes Therapeutics, Inc. (Phanes) announced today that it has entered into a clinical supply agreement with Roche to study PT217, its first-in-class bispecific antibody targeting DLL3 and CD47, in combination with Roche’s anti-PD-L1 therapy, atezolizumab, in patients with small cell lung cancer (SCLC), large cell neuroendocrine carcinoma of the lung (LCNEC) and extrapulmonary neuroendocrine carcinomas (EP-NECs).
May 8, 2024
·
3 min read
Press Releases
Phanes Therapeutics’ PT217 granted Fast Track Designation by the FDA for NEPC
December 5, 2024
·
2 min read
Biotech Beach
Phanes Therapeutics’ PT217 granted Fast Track Designation by the FDA
Phanes Therapeutics, Inc. (Phanes) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PT217 for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression following platinum chemotherapy with or without a checkpoint inhibitor.
April 8, 2024
·
2 min read
Biotech Beach
Phanes Therapeutics, Inc. announces granting of registered trademarks for its three proprietary technology platforms by the U.S. Patent and Trademark Office
Phanes Therapeutics, Inc. announced that the U.S. Patent and Trademark Office has granted the registration of trademarks for its proprietary technology platforms PACbody®, SPECpair® and ATACCbody®.
January 29, 2024
·
2 min read
Press Releases
Phanes Therapeutics Announces the Appointment of Gastrointestinal Oncologist Prof. Zev Wainberg to its Clinical Advisory Board
November 6, 2024
·
2 min read
Biotech Beach
Phanes Therapeutics’ PT886 granted Fast Track designation for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma by the FDA
Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PT886 for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma.
March 20, 2024
·
2 min read
Drug Development
Phanes Therapeutics Announces First Patient Dosed in Clinical Study of PT886 in Combination with KEYTRUDA® (pembrolizumab)
October 8, 2024
·
2 min read
Drug Development
Phanes Therapeutics Announces First Patient Dosed in Clinical Study of PT886 in Combination with Chemotherapy
September 9, 2024
·
2 min read
Press Releases
Phanes Therapeutics’ PT217 receives Orphan Drug Designation for Neuroendocrine Carcinoma from the FDA
August 19, 2024
·
2 min read
1 of 71,222
Next